5-fluorouracil + semustine + streptozotocin + vincristine

This is a combination chemotherapy regimen consisting of four cytotoxic agents: - **5-fluorouracil (5-FU):** A pyrimidine antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in rapidly dividing cells. - **Semustine (methyl-CCNU):** An alkylating nitrosourea compound that crosslinks DNA and RNA, inhibiting replication and transcription. - **Streptozotocin:** An alkylating agent with selective toxicity for pancreatic beta cells; it also causes DNA damage in tumor cells. - **Vincristine:** A vinca alkaloid that binds tubulin and inhibits microtubule formation, arresting cell division at metaphase. The combination has been studied primarily for the treatment of advanced or metastatic colorectal carcinoma and pancreatic carcinoma. The addition of streptozotocin to the classic MOF regimen (semustine/methyl-CCNU, vincristine, 5-fluorouracil) was shown to improve remission rates but increased gastrointestinal toxicity[1][2][3][6]. This regimen is sometimes referred to as "MOF-Strep" or "MOF-S"[1][2][3][6].

Other names

methyl-CCNU + 5-fluorouracil + vincristine + streptozotocinMOF-StrepMOF-S